Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma.

Lin, Dengqiang; Lai, Peng; Zhang, Wen; Lin, Jinglai; Wang, Hang; Hu, Xiaoyi; Guo, Jianming

Lin, Dengqiang; Lai, Peng; Zhang, Wen; Lin, Jinglai; Wang, Hang; Hu, Xiaoyi; Guo, Jianming.

Afiliación

Lin D; Department of Urology, Zhongshan Hospital (Xiamen Branch), Fudan University, Xiamen, China.
Lai P; Department of Urology, Zhongshan Hospital (Xiamen Branch), Fudan University, Xiamen, China.
Zhang W; Department of Traditional Chinese Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Lin J; Department of Urology, Zhongshan Hospital (Xiamen Branch), Fudan University, Xiamen, China.
Wang H; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Hu X; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Guo J; Department of Urology, Zhongshan Hospital (Xiamen Branch), Fudan University, Xiamen, China.

Front Oncol ; 13: 1071816, 2023.

Article en En | MEDLINE | ID: mdl-36874101

Palabras clave

axitinib; nomogram; receiver operating characteristic; renal cell carcinoma; tyrosine kinase inhibitor

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google